Current strategies to protect children from malaria—administration of new RTS,S/AS01 or R21/Matrix-M vaccines as well as seasonal medications—require about 20 health care visits by the time a child reaches age 5 years. However, an approach involving the annual administration of a monoclonal antibody might provide similar malaria protection while reducing health care visits, a randomized clinical trial found.
